Once-daily oral icotrokinra outperforms placebo in ulcerative colitis

For patients with moderately to severely active ulcerative colitis, oral icotrokinra, a peptide that blocks the interleukin-23 receptor, yields a clin…

Continue in Briflio to read, react, comment, and share.